Why CVRx, Inc.’s (CVRX) Stock Is Down 22.78%
As of Wednesday, September 30, CVRx, Inc.’s CVRX share price has dipped by 22.78%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Commentary & Analysis
Why CVRx, Inc.’s (CVRX) Stock Is Down 27.38%
As of Wednesday, September 30, CVRx, Inc.’s CVRX share price has dipped by 27.38%, which has investors questioning if this is right time to buy.Omar Beirat
Why CVRx, Inc.’s (CVRX) Stock Is Down 5.15%
As of Thursday, September 24, CVRx, Inc.’s CVRX share price has dipped by 5.15%, which has investors questioning if this is right time to buy.Michael Rose
Why CVRx, Inc.’s (CVRX) Stock Is Down 5.18%
As of Wednesday, September 09, CVRx, Inc.’s CVRX share price has dipped by 5.18%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why CVRx, Inc.’s (CVRX) Stock Is Up 8.27%
As of Monday, August 24, CVRx, Inc.’s CVRX share price has surged by 8.27%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | CVRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $39.4 | $379.5 | 14% |
|
| Shares Out (Mil) | 26.5 | 40.7 | 35% |
|
| Institutional Ownership | 96.3% | 82.8% | 69% |
|
| Float (Mil) | 18.3 | 35.1 | 27% |
|
| Beta | 0.82 | 0.87 | 49% |
|
| Avg Daily Volume (000s) | 1,057 | 322 | 71% |
|
| Price Change (52-week) |
(83.8%) | 63.2% | 7% |
|
| Growth | CVRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 56.2% | 11.8% | 96% |
|
| Net Income (5yr) | (30.5%) | (5.6%) | 13% |
|
| EPS (5yr) | 44.0% | 10.2% | 91 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.0%) | (15.5%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 7 | |
| Current EPS | ($0.503) | ($2.017) | ($1.877) | |
| Month Ago EPS | ($0.503) | ($2.017) | ($1.877) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.484) | ($1.963) | ($1.894) | |
| Year/Year Chg | (5.1%) | (1.3%) | (16.8%) | |
| Financials | CVRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $61 | $141 | 22% |
|
| Net Income (TTM) (Mil) | ($52) | ($9) | 16% |
|
| EPS (TTM) | ($1.975) | ($0.400) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($41) | ($2) | 11% |
|
| Net Cash Flow (TTM) (Mil) | ($30) | $1 | 23% |
|
| Long-Term Debt (Q1) (Mil) | $59 | $26 | 40% |
|
| Enterprise Value (Q1) (Mil) | $59 | $390 | 17% |
|
| Valuation | CVRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.97 | 2.59 | 52% |
|
| P/E | na | 24.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.5 | na |
|
| Ratios | CVRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 86.9% | 58.7% | 92% |
|
| Net Margin | (84.9%) | (6.9%) | 8% |
|
| ROA | (49.1%) | (12.2%) | 12% |
|
| ROE | (133.4%) | (10.7%) | 7% |
|
| Liabilities to Assets | 78.4% | 47.2% | 74% |
|
| F-Score | 4 | 4 | 33% |
|
CVRx, Inc. did not pass any screens on 10/12/2026.
